# Emricasan, an Oral Caspase Inhibitor, in Subjects With NASH Cirrhosis and Severe Portal Hypertension

Study · id `cardio:ct-nct02960204` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02960204](<https://clinicaltrials.gov/study/NCT02960204>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT02960204

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 263 participants.

## Technical summary

Registry record NCT02960204. Randomized; triple masking; primary purpose treatment. Start 2016-10-17 (actual); primary completion 2018-10-02 (actual). Results posted on 2022-01-14.

## Key facts

- Design: Interventional study; randomized; triple masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 263 participants (enrolled count; ClinicalTrials.gov record NCT02960204, source copy `cardio:ctgov-nct02960204-2022-02-11`, retrieved 2026-10-31)
- Started: 2016-10-17 (actual) (ClinicalTrials.gov record NCT02960204, source copy `cardio:ctgov-nct02960204-2022-02-11`, retrieved 2026-10-31)
- Primary completion: 2018-10-02 (actual) (ClinicalTrials.gov record NCT02960204, source copy `cardio:ctgov-nct02960204-2022-02-11`, retrieved 2026-10-31)
- Completion: 2019-04-08 (actual) (ClinicalTrials.gov record NCT02960204, source copy `cardio:ctgov-nct02960204-2022-02-11`, retrieved 2026-10-31)
- Results first posted: 2022-01-14 (ClinicalTrials.gov record NCT02960204, source copy `cardio:ctgov-nct02960204-2022-02-11`, retrieved 2026-10-31)
- Countries: United States; Germany; Spain (ClinicalTrials.gov record NCT02960204, source copy `cardio:ctgov-nct02960204-2022-02-11`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02960204-2022-02-11`, retrieved 2026-10-31)

## The registry's words

- Brief title: Emricasan, an Oral Caspase Inhibitor, in Subjects With NASH Cirrhosis and Severe Portal Hypertension
- Acronym: ENCORE-PH
- Condition: Cirrhosis
- Condition: Portal Hypertension
- Condition: Non-alcoholic Steatohepatitis
- Intervention (Drug): Emricasan
- Intervention (Drug): Placebo
- Lead sponsor: Histogen
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Fatty liver disease (NAFLD / MASLD) (`cardio:nafld`)

### Main results

- Registry lists this paper as a reference of type result; PubMed types it as a trial report that names this trial and no other, dated on or after the trial start, and its title marks no secondary, follow-up or other further analysis: Randomized placebo-controlled trial of emricasan for non-alcoholic steatohepatitis-related cirrhosis with severe portal hypertension (`cardio:pubmed-31870950`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 580cca8b994119a868336430f69c699dcdf1539366f06ec3b25c97e1f11a0431
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
